{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:50:27Z","timestamp":1783421427693,"version":"3.54.6"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.drudis.2021.05.018","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T04:22:16Z","timestamp":1623298936000},"page":"2182-2189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Improving the ability of antimicrobial susceptibility tests to predict clinical outcome accurately: Adding metabolic evasion to the equation"],"prefix":"10.1016","volume":"26","author":[{"given":"Jason","family":"Tasse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenna\u00eblle","family":"Dieppois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Peyrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Tesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.05.018_b0005","unstructured":"Interagency Coordination Group on Antimicrobial Resistance. No time to wait: securing the future from drug-resistant infections. https:\/\/www.who.int\/antimicrobial-resistance\/interagency-coordination-group\/IACG_final_report_EN.pdf?ua=1. Published April, 2019. Accessed 21 May, 2021."},{"key":"10.1016\/j.drudis.2021.05.018_b0010","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/jac\/dkq217","article-title":"The 2009 Garrod Lecture: the evolution of antimicrobial resistance: a Darwinian perspective","volume":"65","author":"Sykes","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.drudis.2021.05.018_b0015","unstructured":"The European Committee on Antimicrobial Susceptibility Testing \u2013 EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_10.0_Breakpoint_Tables.pdf. Published 1 January, 2020. Accessed 21 May, 2021."},{"key":"10.1016\/j.drudis.2021.05.018_b0020","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","article-title":"The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach","volume":"18","author":"Mouton","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.drudis.2021.05.018_b0025","unstructured":"The European Committee on Antimicrobial Susceptibility Testing \u2013 EUCAST. New definitions of S, I and R from 2019. https:\/\/www.eucast.org\/newsiandr\/. Published 2019. Accessed 21 May, 2021."},{"issue":"9 Supplement","key":"10.1016\/j.drudis.2021.05.018_b0030","first-page":"S11","article-title":"The clinical predictive value (or lack thereof) of the results of in vitro antimicrobial susceptibility tests","volume":"49","author":"Doern","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.drudis.2021.05.018_b0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ebiom.2017.07.002","article-title":"The accidental orthodoxy of Drs. Mueller and Hinton","volume":"22","author":"Nizet","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drudis.2021.05.018_b0040","unstructured":"ISO. ISO 20776-1:2019. https:\/\/www.iso.org\/standard\/70464.html. Published June, 2019. Accessed 21 May, 2021."},{"key":"10.1016\/j.drudis.2021.05.018_b0045","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3390\/pharmaceutics12080773","article-title":"Use of supplemented or human material to simulate PD behavior of antibiotics at the target site in vitro","volume":"12","author":"Nussbaumer-Pr\u00f6ll","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2021.05.018_b0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2017.05.026","article-title":"Correcting a fundamental flaw in the paradigm for antimicrobial susceptibility testing","volume":"20","author":"Ersoy","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drudis.2021.05.018_b0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000494757","article-title":"Influence of laboratory culture media on in vitro growth, adhesion, and biofilm formation of Pseudomonas aeruginosa and Staphylococcus aureus","volume":"28","author":"Wijesinghe","year":"2019","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.drudis.2021.05.018_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011818","article-title":"A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections","volume":"5","author":"Hu","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2021.05.018_b0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10409238.2013.869543","article-title":"Persisters and beyond: mechanisms of phenotypic drug resistance and drug tolerance in bacteria","volume":"49","author":"Kester","year":"2014","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.drudis.2021.05.018_b0070","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrmicro.2016.34","article-title":"Distinguishing between resistance, tolerance and persistence to antibiotic treatment","volume":"14","author":"Brauner","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.drudis.2021.05.018_b0075","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.tim.2013.06.002","article-title":"The in vivo biofilm","volume":"21","author":"Bjarnsholt","year":"2013","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.drudis.2021.05.018_b0080","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1128\/MMBR.00013-14","article-title":"Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics","volume":"78","author":"Lebeaux","year":"2014","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.drudis.2021.05.018_b0085","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41579-019-0196-3","article-title":"Definitions and guidelines for research on antibiotic persistence","volume":"17","author":"Balaban","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.drudis.2021.05.018_b0090","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.3748\/wjg.v23.i27.4867","article-title":"Significance of dormant forms of Helicobacter pylori in ulcerogenesis","volume":"23","author":"Reshetnyak","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.drudis.2021.05.018_b0095","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2741\/1293","article-title":"The search for new sterilizing anti-tuberculosis drugs","volume":"9","author":"Mitchison","year":"2004","journal-title":"Front Biosci"},{"key":"10.1016\/j.drudis.2021.05.018_b0100","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrmicro2236","article-title":"The spectrum of latent tuberculosis: rethinking the biology and intervention strategies","volume":"7","author":"Barry","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.drudis.2021.05.018_b0105","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/0092-8674(92)90079-R","article-title":"Unipolar cell divisions in the yeast S. cerevisiae lead to filamentous growth: regulation by starvation and RAS","volume":"68","author":"Gimeno","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2021.05.018_b0110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhin.2010.03.012","article-title":"Risk factors for treatment failure in patients with prosthetic joint infections","volume":"75","author":"Lee","year":"2010","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.drudis.2021.05.018_b0115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2036.2002.01169.x","article-title":"Current concepts in the management of Helicobacter pylori infection\u2014the Maastricht 2\u20132000 Consensus Report","volume":"16","author":"Malfertheiner","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.drudis.2021.05.018_b0120","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrmicro1557","article-title":"Persister cells, dormancy and infectious disease","volume":"5","author":"Lewis","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.drudis.2021.05.018_b0125","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/jac\/dkp007","article-title":"Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis","volume":"63","author":"Gillham","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.drudis.2021.05.018_b0130","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2014.10.024","article-title":"ESCMID guideline for the diagnosis and treatment of biofilm infections 2014","volume":"21","author":"H\u00f8iby","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.drudis.2021.05.018_b0135","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2021.05.018_b0140","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1128\/AAC.02420-12","article-title":"High activity of fosfomycin and rifampin against methicillin resistant Staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model","volume":"58","author":"Mihailescu","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2021.05.018_b0145","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1378\/chest.123.5.1495","article-title":"Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis","volume":"123","author":"Smith","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.drudis.2021.05.018_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2010.05.006","article-title":"Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial","volume":"8","author":"Cammarota","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2021.05.018_b0155","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1086\/320519","article-title":"Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with Darier\u2019s disease","volume":"32","author":"von Eiff","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.drudis.2021.05.018_b0160","first-page":"ciaa839","article-title":"Apparent intracellular Helicobacter pylori detected by immunohistochemistry \u2013 the missing link in eradication failure","author":"Beer","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.drudis.2021.05.018_b0165","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1128\/AAC.01125-12","article-title":"Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis","volume":"56","author":"Zhang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2021.05.018_b0170","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/AAC.04359-14","article-title":"Antimicrobial activity against intraosteoblastic Staphylococcus aureus","volume":"59","author":"Valour","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2021.05.018_b0175","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/AAC.01135-08","article-title":"Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1 macrophages and keratinocytes) forms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus","volume":"53","author":"Lemaire","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2021.05.018_b0180","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1128\/AAC.01145-08","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2021.05.018_b0185","doi-asserted-by":"crossref","first-page":"e00084","DOI":"10.1128\/CMR.00084-16","article-title":"Options and limitations in clinical investigation of bacterial biofilms","volume":"31","author":"Magana","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2021.05.018_b0190","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nprot.2010.71","article-title":"Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening","volume":"5","author":"Harrison","year":"2010","journal-title":"Nat Protoc"},{"key":"10.1016\/j.drudis.2021.05.018_b0195","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jcf.2014.09.013","article-title":"Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients","volume":"14","author":"Yau","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.drudis.2021.05.018_b0200","first-page":"2437","article-title":"Microtiter dish biofilm formation assay","volume":"47","author":"O\u2019Toole","year":"2011","journal-title":"J Vis Exp"},{"key":"10.1016\/j.drudis.2021.05.018_b0205","unstructured":"Food and Drug Administration. Microbiology data for systemic antibacterial drugs\u2014development, analysis, and presentation: guidance for industry. https:\/\/www.fda.gov\/media\/77442\/download. Published February, 2018. Accessed 21 May, 2021."},{"key":"10.1016\/j.drudis.2021.05.018_b0210","unstructured":"European Medicines Agency. Evaluation of medicinal products indicated for treatment of bacterial infections. https:\/\/www.ema.europa.eu\/en\/evaluation-medicinal-products-indicated-treatment-bacterial-infections. Published 14 January, 2019. Accessed 21 May, 2021."},{"key":"10.1016\/j.drudis.2021.05.018_b0215","unstructured":"European Medicines Agency. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf. Published 21 July, 2016. Accessed 21 May, 2021."},{"key":"10.1016\/j.drudis.2021.05.018_b0220","unstructured":"EN 14885 November 2018 - Chemical disinfectants and antiseptics - Application of European Standards for chemical disinfectants and antiseptics. https:\/\/www.boutique.afnor.org\/standard\/nf-en-14885\/chemical-disinfectants-and-antiseptics-application-of-european-standards-for-chemical-disinfectants-and-antiseptics\/article\/903044\/fa189006."},{"key":"10.1016\/j.drudis.2021.05.018_b0225","unstructured":"Food and Drug Administration. Guidance for industry pulmonary tuberculosis: developing drugs for treatment. https:\/\/www.fda.gov\/media\/87194\/download. Published November, 2013. Accessed 21 May, 2021."},{"key":"10.1016\/j.drudis.2021.05.018_b0230","unstructured":"BEAM Alliance. A new vision for AMR innovation to support medical care. https:\/\/beam-alliance.eu\/wp-content\/uploads\/2019\/10\/beam-alliance-a-new-vision-to-support-amr-innovation.pdf. Published April, 2019. Accessed 21 May, 2021."},{"key":"10.1016\/j.drudis.2021.05.018_b0235","series-title":"Mims\u2019 pathogenesis of infectious disease","author":"Nash","year":"2016"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621002518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621002518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:53:10Z","timestamp":1761223990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621002518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1359644621002518"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.05.018","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving the ability of antimicrobial susceptibility tests to predict clinical outcome accurately: Adding metabolic evasion to the equation","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}